One-day vs five-day of octreotide infusion along with endoscopic therapy in the prevention of early rebleeding and mortality from esophageal varices: randomized control trial

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20221004008

Enrollment

236

Registered

2022-10-04

Start date

2022-09-29

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis with esophageal varices bleeding esophageal varices bleeding

Interventions

-After endoscopic therapy (variceal banding ligation) -Octreotide was continuously given via intravenous route at rate of 50 microgram/hour for 1 day (24 hours) -Observe for variceal rebleeding in 5 d

Experimental Drug,Experimental Drug

One-day of octreotide infusion , five-day of octreotide infusion

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: esophageal varices bleeding cirrhosis Age >20 years

Exclusion criteria

Exclusion criteria: Non-cirrhosis Other source of bleeding Concomitant GV Failure to stop bleeding via endoscope U/D: HCC, advanced malignancy, septic shock Deny to participate

Design outcomes

Primary

Measure	Time frame
5 day rebleeding 5 day rebleeding rate,6 weeks mortality 6 weeks mortality rate	—

Secondary

Measure	Time frame
6 weeks rebleeding 6 weeks rebleeding rate	—

Countries

Thailand

Contacts

Public ContactKanit Bunnag

Phramongkutklao Hospital

pmkmedicine@gmail.com6627639300

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026